Ratings Medacta Group SA

Equities

MOVE

CH0468525222

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe Europe Other stock markets 04:57:35 2024-12-11 am EST			5-day change	1st Jan Change
109.70 ^CHF	-0.09%		-0.54%	-12.74%

Sep. 25	Swiss Market Index Advances Ahead of SNB's Rate Decision Day	MT
Sep. 25	Medacta Group SA - Analyst/Investor Day

Summary: Medacta Group SA

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Highlights: Medacta Group SA

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 46% by 2026.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses: Medacta Group SA

The company benefits from high valuations in earnings multiples.
With an enterprise value anticipated at 3.99 times the sales for the current fiscal year, the company turns out to be overvalued.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings Chart: Medacta Group SA

Source: Surperformance

ESG chart: Medacta Group SA

Source: Refinitiv

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Fundamentals	Composite Valuation	Composite Momentum	Capi. ($)
	MEDACTA GROUP SA				2.48B
	ABBOTT LABORATORIES				200B
	MEDTRONIC PLC				107B
	BECTON, DICKINSON AND COMPANY				64.02B
	HOYA CORPORATION				46.64B
	CENCORA, INC.				45.81B
	DEXCOM, INC.				31.02B
	TERUMO CORPORATION				29.46B
	WEST PHARMACEUTICAL SERVICES, INC.				23.12B
	ZIMMER BIOMET HOLDINGS, INC.				21.58B
	Average				57.16B
	Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes